Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

– Renee Gala named as President and CEO, effective August 11 –

– Total revenues of $1.05 billion in 2Q25 –

– Xywav^® revenues grew 13% year-over-year, with robust net patient adds of 625 quarter-over-quarter –

Read more at prnewswire.com